National Center for Advancing Translational Sciences; Notice of Meetings, 50069-50070 [2013-19899]

Download as PDF Federal Register / Vol. 78, No. 159 / Friday, August 16, 2013 / Notices applications and the discussions would likely to significantly frustrate implementation of recommendations. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: September 3, 2013. Time: 4:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications for the Pioneer and New Innovator Awards. Place: National Institutes of Health, Building 1, 126, 1 Center Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 103, Bethesda, MD 20892, 301–496–4272, woodgs@od.nih.gov. Information is also available on the Institute’s/Center’s home page: https:// acd.od.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: August 12, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2013–19896 Filed 8–15–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health emcdonald on DSK67QTVN1PROD with NOTICES Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member VerDate Mar<15>2010 19:06 Aug 15, 2013 Jkt 229001 conflict: Pain and Chemosensory Neuroscience. Date: August 27–28, 2013. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: John Bishop, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5182, MSC 7844, Bethesda, MD 20892, (301) 408– 9664, bishopj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Shared Instruments: Mass Spectrometers. Date: September 10–11, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: David R. Jollie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4150, MSC 7806, Bethesda, MD 20892, (301) 435– 1722, jollieda@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Shared Instrumentation: Ultrasound and Optical. Date: September 10, 2013. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Jan Li, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, Bethesda, MD 20892, 301–435–1049, lij21@ csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Prevention and Treatment. Date: September 10, 2013. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Lawrence Ka-Yun Ng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301–435– 1719, ngkl@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Investigations on Primary Immunodeficiency Diseases. Date: September 10, 2013. Time: 12:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Scott Jakes, Ph.D., Scientific Review Officer, Center for PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 50069 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4198, MSC 7812, Bethesda, MD 20892, 301–495– 1506, jakesse@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cell Biology. Date: September 11–12, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jonathan Arias, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7840, Bethesda, MD 20892, 301–435– 2406, ariasj@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: August 8, 2013. Carolyn A. Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–19905 Filed 8–15–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Advancing Translational Sciences; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Center for Advancing Translational Sciences. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. E:\FR\FM\16AUN1.SGM 16AUN1 50070 Federal Register / Vol. 78, No. 159 / Friday, August 16, 2013 / Notices Name of Committee: Cures Acceleration Network Review Board. Date: September 16, 2013. Time: 8:30 a.m. to 2:30 p.m. Agenda: Report from the Institute Director. Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Danilo A Tagle, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 992, Bethesda, MD 20892, 301–594–8064, Danilo.Tagle@nih.gov. Name of Committee: National Center for Advancing Translational Sciences Advisory Council. Date: September 16, 2013. Open: 8:30 a.m. to 2:30 p.m. Agenda: Report from the Institute Director and other staff. Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Closed: 2:45 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Danilo A Tagle, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 992, Bethesda, MD 20892, 301–594–8064, Danilo.Tagle@nih.gov. Dated: August 8, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–19899 Filed 8–15–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request emcdonald on DSK67QTVN1PROD with NOTICES Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. Project: Cross-site Evaluation of the Garrett Lee Smith Memorial Suicide Prevention and Early Intervention Programs (OMB No. 0930–0286)— Revision The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Mental Health Services (CMHS) will continue to conduct the cross-site evaluation of the VerDate Mar<15>2010 19:06 Aug 15, 2013 Jkt 229001 Garrett Lee Smith Memorial Youth Suicide Prevention and Early Intervention State/Tribal Programs and the Garrett Lee Smith Memorial Youth Suicide Prevention Campus Programs. The data collected through the cross-site evaluation addresses four stages of program activity: (1) The context stage includes a review of program plans, such as grantee’s target population, target region, service delivery mechanisms, service delivery setting, types of program activities to be funded and evaluation activities; (2) the product stage describes the prevention strategies that are developed and utilized by grantees; (3) the process stage assesses progress on key activities and milestones related to implementation of program plans; and (4) the impact 1 stage assesses the impact of the program on early identification, referral for services, and service follow-up of youth at risk. To date, 147 State/Tribal cooperative agreement awardees and 153 Campus grantees have participated in the crosssite evaluation since FY 2005. Currently, 61 State/Tribal cooperative agreement awardees and 60 Campus grantees are participating in the crosssite evaluation. Data will continue to be collected from suicide prevention program staff (e.g., project directors, evaluators), key program stakeholders (e.g., state/local officials, child-serving agency directors, gatekeepers, mental health providers, and campus administrators), training participants, college students, and campus faculty/ staff through FY2016. Since the State/Tribal grantees differ from the Campus grantees in programmatic approaches, specific data collection activities also vary by type of program. The following describes the specific data collection activities and data collection instruments to be used across State/Tribal and Campus grantees for the cross-site evaluation. While most of the data collection instruments described below are revised versions of instruments that have previously received Office of Management and Budget approval (OMB No. 0930–0286 with Expiration Date: August 2013) and 1 The evaluation as designed includes four stages (context, content, process, and impact) each of which is hinged to the fundable activities of the grantees, the research questions outlined in the evaluation statement of work, and the state of the knowledge base in the field of suicide prevention. As such, while the evaluation design does not currently include rigorous impact assessment, it does include the comparative assessment of proximal outcomes as a part of the impact stage. Hereafter, the impact stage is used as an umbrella term to cover evaluation protocols designed and implemented to understand the outcomes of the program. PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 are currently in use, new instruments include: • The Training Utilization and Preservation—Survey (TUP–S): 6Month Follow-up, Adolescent, and Campus Versions • The Life skills Activities Follow-up Interview (LAI) • The Coalition Survey • The Coalition Profile • The Short Message Service Survey (SMSS) • The Student Awareness Intercept Survey (SAIS) The addition of these new data collection activities does not increase the burden associated with the cross-site evaluation because several lengthy instruments, as well as campus case studies, have been removed from the data collection protocol. A summary table of the number of respondents and respondent burden has also been included. Previously approved instruments that have been removed include: • The Training Exit Survey (TES) Individual Form for States/Tribes • The Suicide Prevention, Exposure, Awareness and Knowledge Survey for Students (SPEAKS–S)_ • The Campus Infrastructure Interviews (CIFI) • Three instruments collected by a subset of Campus grantees • The Training Utilization and Preservation Interview (TUP–I) Data Collection Activities for State/ Tribal Grantees For State/Tribal grantees, the Prevention Strategies Inventory State/ Tribal (PSI–ST) Baseline and Follow-up, Referral Network Survey (RNS), and the Training Utilization and Preservation— Survey (TUP–S–ST): State/Tribal Version described below are revised versions of instruments that previously received OMB approval (OMB No. 0930–0286 with Expiration Date: August 2013) and are currently in use. The Training Activity Summary Page State/ Tribal (TASP–ST), Early Identification, Referral and Follow-up Screening Form (EIRF–S) and the Early Identification, Referral and Follow-up Analysis (EIRF) are data collection activities that utilize existing data sources. The Training Utilization and Preservation Survey (TUP–S): 6-Month Follow-up and Adolescent Versions, the Coalition Profile, and the Coalition Survey are proposed as new data collection instruments. Prevention Strategies Inventory-State/ Tribal (PSI–ST)—Revised: The Prevention Strategies Inventory will collect information on the suicide E:\FR\FM\16AUN1.SGM 16AUN1

Agencies

[Federal Register Volume 78, Number 159 (Friday, August 16, 2013)]
[Notices]
[Pages 50069-50070]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19899]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of meetings of the 
National Center for Advancing Translational Sciences.
    The meetings will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


[[Page 50070]]


    Name of Committee: Cures Acceleration Network Review Board.
    Date: September 16, 2013.
    Time: 8:30 a.m. to 2:30 p.m.
    Agenda: Report from the Institute Director.
    Place: National Institutes of Health, Building 31, Conference 
Room 6, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Danilo A Tagle, Ph.D., Executive Secretary, 
National Center for Advancing Translational Sciences, 1 Democracy 
Plaza, Room 992, Bethesda, MD 20892, 301-594-8064, 
Danilo.Tagle@nih.gov.

    Name of Committee: National Center for Advancing Translational 
Sciences Advisory Council.
    Date: September 16, 2013.
    Open: 8:30 a.m. to 2:30 p.m.
    Agenda: Report from the Institute Director and other staff.
    Place: National Institutes of Health, Building 31, Conference 
Room 6, 31 Center Drive, Bethesda, MD 20892.
    Closed: 2:45 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, Conference 
Room 6, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Danilo A Tagle, Ph.D., Executive Secretary, 
National Center for Advancing Translational Sciences, 1 Democracy 
Plaza, Room 992, Bethesda, MD 20892, 301-594-8064, 
Danilo.Tagle@nih.gov.

    Dated: August 8, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.


[FR Doc. 2013-19899 Filed 8-15-13; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.